NOX4 inhibition has shown to overcome the CD8+ T cell exclusion and potentiate anti-PD1 immunotherapy response using in vivo murine breast cancer model [274] (Fig. 2). GKT137831 is a NOX4/1 inhibitor reported to repress CAF-mediated immune tolerance [275, 276]. This evidence concerns the gene CD8A and breast cancer.